Open AccessLate PET/CT Findings of COVID-19 Pneumonia With 2 Different Radiopharmaceuticals in a Patient
Author(s) -
Özlem Öztürk Şahin,
Buğra Kaya,
Zeynep Banu Aydın,
Mustafa Karaağaç,
Gül Kanyılmaz
Publication year - 2021
Publication title -
clinical nuclear medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.637
H-Index - 57
eISSN - 1536-0229
pISSN - 0363-9762
DOI - 10.1097/rlu.0000000000003720
Subject(s) - medicine , pneumonia , covid-19 , prostate cancer , lung , lung cancer , nuclear medicine , positron emission tomography , radiology , cancer , pathology , disease , infectious disease (medical specialty) , outbreak
We present the 68Ga-PSMA and 18F-FDG PET/CT findings comparatively of a 67-year-old prostate cancer and malignant melanoma patient who had COVID-19 pneumonia 3 months ago. In 68Ga-PSMA PET/CT, ground-glass opacities showing markedly increased PSMA uptake were observed in the patient's lungs. It was learned that the patient had COVID-19 pneumonia 3 months ago and was treated in the intensive care unit for 13 days. In 18F-FDG PET/CT, FDG uptake was minimal in the same areas. In the midterm period after COVID-19 pneumonia, lung PSMA uptake is more intense than FDG, which may help better understand the disease's healing phase.